G2B PHARMA
G2B Pharma’s research is focused on the development of a needle -free alternative for epinephrine using the nasal delivery route. G2B is partnering in this effort with Shin Nippon Biological Laboratories of Japan, a leading developer of nasal spray devices and delivery systems. Millions of people are at risk for anaphylaxis, a severe and life-threatening allergic reaction that can include rash, swelling of the tongue and throat, and a sudden drop in blood pressure. The most common causes of an... aphylactic reactions are food allergies and insect stings. Less common causes are latex allergy, drug allergies and animal bites. Epinephrine autoinjectors became available in the early 1980s, allowing patients to self-administer epinephrine when experiencing the onset of anaphylaxis. To date, over 50 million autoinjectors have been dispensed. Yet the population at-risk for anaphylaxis far exceeds the number individuals having autoinjectors. This is thought to be due to the fact that many patients and caregivers have difficulty properly using autoinjectors and many are reluctant to use them due to fear of needles.
G2B PHARMA
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2008-01-01
Address:
Corte Madera, California, United States
Country:
United States
Website Url:
http://www.g2bpharma.com
Total Employee:
1+
Status:
Active
Contact:
415-515-7614
Total Funding:
235 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Microsoft Exchange Online Office 365 Mail GoDaddy DNS Google Google Cloud OpenResty Google Adsense
Similar Organizations
Axcella
Axcella is a biotechnology company providing therapeutics development solutions.
Dauntless Pharmaceuticals
Dauntless Pharmaceuticals is a biotechnology company that focuses on the development of drugs.
Evolugate
Evolugate is a technology provider in the evolutionary optimization of micro-organisms.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Current Advisors List
Current Employees Featured
